Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphomay

Hematological Oncology

Volumn 28, Issue 2, 2010, Pages 68-74

  Niitsu, Nozomi ^a,b   Kohri, Mika ^a   Hagiwara, Yuki ^a   Tanae, Ken ^a   Takahashi, Naoki ^a   Bessho, Masami ^a   Okamoto, Masataka ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Adult Lymphoma Treatment Study Group ALTSG   (Japan)

Author keywords

CyclOBEAP; Diffuse large b cell lymphoma; Rituximab; Soluble interleukin 2 receptor

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM; VINCRISTINE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURA'; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEUTROPENIA; PREDNISOLONE; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 77953267128     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.940     Document Type: Article

References (23)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-2795.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 3121-3127.
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
5. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
6. Tilly H, Lepage E, Coiffier B, et al. Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poorprognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-4289.
7. Niitsu N, Okamoto M, Aoki S, et al. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol 2006; 85: 374-380.
8. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
9. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109: 4930-4935.
10. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008; 26: 4587-4594.
11. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Volume 2. IARC WHO Classification of Tumours, No 2. IARC Press: Lyon, France, 2008.
12. Cheson BD, Pfistner B, Juweid ME, et al. The international harmonization project on lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945; 1: 80-83.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
16. Cox DR. Regression models and life tables. J Stat Soc Br 1972; 34: 187-202.
17. Shipp MA. International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
18. Gisselbrecht C, Fitoussi O, Belhadj K, et al. Survival impact of rituximab combined to ACVBP (R-ACVBP) in 209 poor risk diffuse large B-cell lymphoma (DLBCL) patients treated with upfront high-dose consolidative autotransplantation (HDC): a GELA phase II study. Blood (ASH Annual Meeting Abstracts) 2008; 112: 771.
19. Glass B, Kloess M, Bentz M, et al. German high-grade nonhodgkin lymphoma study group. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006; 107: 3058-3064.
20. Stewart DA, Bahlis N, Valentine K, et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006; 107: 4623-4627.
21. Vitolo U, Chiappella A, Angelucci E, et al. Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL). Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009; 94: 1250-1258.
22. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and postgerminal center biomarkers. J Clin Oncol 2008; 26: 2717-2724.
23. Tarella C, Zanni M, Di Nicola M, et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21: 1802-1811.